Staging and assessing trophoblastic tumors: A possible solution to an intractable problem

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 43, Issue 1, 1998, Pages 33-36

  Kohorn, Ernest I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Nomenclature; Trophoblastic tumors

Indexed keywords

CANCER CLASSIFICATION; CANCER RISK; CANCER STAGING; CONFERENCE PAPER; NOMENCLATURE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; TROPHOBLASTIC TUMOR;

EID: 0031908824     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Einhorn N: Evolution and current status of gynecologic cancer staging. Curr Prob Obstet Gynecol Fertit 1992;15:251-268
2. Bagshawe KD: Risk and prognostic factors in trophoblastic disease. Cancer 1976;38:1373-1385
3. Goldstein DP, Berkowitz RS: Gestational Trophoblastic Neoplasia: Clinical Principles of Diagnosis and Management. Philadelphia, WB Saunders, 1982, p 119
4. World Health Organization Scientific Group on Gestational Trophoblastic Diseases: Technical Report Series No. 692. Geneva, WHO, 1983
5. Kohorn EI: The trophoblastic tower of Babel: Classification systems from metastatic gestational trophoblastic neoplasia. Gynecol Oncol 1995;56:280-288
6. Bagshawe KD, Rawlins G, Pike MC, et al: ABO blood-groups in trophoblastic neoplasia. Lancet 1971;553-557
7. Darwood MY, Teoh ES, Ratnam SS: ABO blood group in trophoblastic disease. J Obstet Gynaecol Br Commonw 1971;78: 918-923
8. Newlands ES, Bagshawe KD, Begent RHJ, et al: Results with the EMA/CO (etoposide, methotrexate, acrinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 1991;98:550-557
9. Bolis G, Bonazzi C, Landoni F, et al: EMA/CO regimen in high risk gestational trophoblastic tumors (GTT). Gynecol Oncol 1988;31:439-444
10. Surwit EA, Childres JM: High-risk metastatic gestational trophoblastic disease: A new dose-intensive, multiagent chemotherapeutic regimen. J Reprod Med 1991;36:45-48
11. Dubuc-Lissoir J, Sweizig S, Schlaerth JB, et al: Metastatic gestational trophoblastic disease: A comparison of prognostic classification systems. Gynecol Oncol 1992;45:40-45
12. Lurain JR, Casanova LA, Miller DS, et al: Prognostic factors in gestational trophoblastic tumors: A proposed new scoring system based on multivariate analysis. Am J Obstet Gynecol 1991;164:611-616
13. Mortakis AE, Braga CA: "Poor prognosis" metastatic gestational trophoblastic disease: The prognostic significance of the scoring system in predicting chemotherapy failures. Obstet Gynecol 1990;76:272-277
14. Gordon AM, Gershenson DM, Copeland LJ, et al: High risk metastatic gestational trophoblastic disease: Further stratification into two clinical entities. Gynecol Oncol 1989; 34:54-56
15. DuBeshter B, Berkowitz RS, Goldstein DP, et al: Analysis of treatment failure in high risk metastatic gestational trophoblastic disease. Gynecol Oncol 1988;29:199-207
16. Soper J, Evans C, Clarke-Pearson D, et al: Alternating weekly chemotherapy with etoposide-methotrexate-actinomycin/cyclophosphamide-vincristine (EMA-CO) for high risk gestational trophoblastic disease (GTD) (abstr). Gynecol Oncol 1994;52:119
17. Wong LC, Choo YC, Ma HK: Modified Bagshawe's regimen in high-risk gestational trophoblastic disease. Gynecol Oncol 1986;23:87-93
18. Azab M, Pejovic MH, Theodore C, et al: Prognostic factors in gestational trophoblastic tumors. Cancer 1988;62:585-592
19. Hammond CB, Borchert LG, Tyrey L, et al: Treatment of metastatic gestational trophoblastic disease: Good and poor prognosis. Am J Obstet Gynecol 1973;115:451-457